Amgen Sustainability Profile
Amgen Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of innovation since its founding in 1980. With a strong presence in major operational regions including Europe and Asia, Amgen focuses on developing therapies in areas such as oncology, nephrology, and inflammation. Renowned for its pioneering biologic medicines, Amgen's core products include Enbrel, Neulasta, and Prolia, which are distinguished by their ability to target specific disease pathways effectively. The company has achieved significant milestones, including the introduction of the first recombinant human erythropoietin, Epogen, which transformed the treatment of anaemia. As a prominent player in the biotechnology industry, Amgen continues to excel, holding a strong market position and receiving numerous accolades for its commitment to scientific excellence and patient care.
DitchCarbon Score
How does Amgen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amgen's score of 51 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amgen's reported carbon emissions
In 2024, Amgen reported total carbon emissions of approximately 1,700,500,000 kg CO2e, with significant contributions from Scope 1 emissions at about 147,000,000 kg CO2e, Scope 2 emissions at approximately 14,000,000 kg CO2e, and a substantial Scope 3 total of about 1,705,000,000 kg CO2e, primarily from upstream transportation and distribution. Amgen has set ambitious climate commitments, aiming for a 55% reduction in absolute Scope 1 and 2 greenhouse gas emissions by 2027, using 2019 as a baseline. The company also plans to achieve 100% renewable electricity sourcing across its operations by 2027, which is expected to result in a reduction of about 50% in carbon emissions from operations. As of 2023, Amgen achieved 54% of its targeted reductions for Scope 1 and 2 emissions. Additionally, Amgen is committed to ensuring that 73% of its suppliers, by spend, covering upstream purchased goods and services and capital goods, will have science-based targets by 2027. The company aims for carbon neutrality in its owned and operated facilities and operations by 2027, encompassing both Scope 1 and Scope 2 emissions. These targets align with the Science Based Targets initiative (SBTi) and reflect Amgen's commitment to addressing climate change within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 144,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 290,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | - | - | 0,000,000,000 |
How Carbon Intensive is Amgen's Industry?
How Carbon Intensive is Amgen's Location?
Amgen's Scope 3 Categories Breakdown
Amgen's Scope 3 emissions, which increased by 814% last year and increased significantly since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Upstream Transportation & Distribution" being the primary emissions source at 87% of Scope 3 emissions.
Top Scope 3 Categories
Amgen's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Amgen has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
